rociletinib + atezolizumab

**rociletinib + atezolizumab** is an investigational combination of a small molecule EGFR tyrosine kinase inhibitor (rociletinib, CO-1686) and an anti–PD-L1 monoclonal antibody (atezolizumab, Tecentriq). Rociletinib selectively inhibits mutant forms of the epidermal growth factor receptor (EGFR), particularly T790M mutations, while sparing wild-type EGFR, thus targeting resistant non-small cell lung cancer (NSCLC). Atezolizumab targets PD-L1, blocking its interaction with PD-1 and B7.1, leading to the restoration and activation of anti-tumor T-cell immune responses. The combination was explored to overcome resistance mechanisms in EGFR-mutant NSCLC, especially post-EGFR inhibitor progression.